Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is October - September.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Revenue Revenue Growth	669.5	829.45	3.55	240.74	243.23	138.29
Revenue Growth	16.84%	23258.15%	-98.52%	-1.03%	75.89%	57.16%
Gross Profit Gross Profit Growth	669.5	829.45	3.55	240.74	243.23	138.29
Operating Income Operating Income Growth	-226.44	98.35	-601.08	-205	-178.51	-149.04
Net Income Net Income Growth	-319.96	-1.63	-599.49	-205.28	-176.06	-140.85
Earnings Per Share EPS Growth	-2.28	-0.01	-5.00	-1.92	-1.67	-1.36
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
GSK GSK Growth	-	2.65	2.69	29.66	124.76	-
Takeda Takeda Growth	-	-	0.87	162.52	85.83	90.78
Sarepta Sarepta Growth	424.07	696.8	-	-	-	-
Sanofi Sanofi Growth	141.98	130	-	-	-	-
Revenue (Total) Revenue (Total) Growth	669.5	829.45	3.55	240.74	243.23	138.29

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cash & Investments Cash & Investments Growth	1,598	917.47	677.46	395.73	369.1	367.79
Total Debt Total Debt Growth	1,379	743.98	851.91	383.5	81.58	25.55
Net Cash (Debt) Net Cash Growth	218.46	173.49	-174.45	12.23	287.52	342.24
Net Cash Growth	22.88%	-	-	-95.75%	-15.99%	16.27%
Net Cash Per Share Net Cash Per Share Growth	1.56	1.30	-1.46	0.11	2.73	3.30

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Operating Cash Flow Operating Cash Flow Growth	-59.06	179.55	-462.85	-153.89	-136.13	171.31
Capital Expenditures CapEx Growth	-16.06	-22.67	-141.47	-176.74	-52.78	-23.57
Free Cash Flow Free Cash Flow Growth	-75.11	156.89	-604.32	-330.63	-188.91	147.75
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-33.82%	11.86%	-16927.06%	-85.16%	-73.39%	-107.77%
Pretax Margin	-37.65%	6.21%	-17247.54%	-85.78%	-71.01%	-101.85%
Profit Margin	-47.79%	-0.20%	-16882.37%	-85.27%	-72.39%	-101.85%
FCF Margin	-11.22%	18.92%	-17018.31%	-137.34%	-77.67%	106.84%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 21, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Forward PE	-	140.94	140.94	140.94	140.94	140.94
P/FCF Ratio	-	30.40	-	-	-	44.06
PS Ratio	14.51	5.75	678.12	11.96	14.38	47.07

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Aug 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Sep 21, 2026

Data Sources Report a data error